CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g., with lenalidomide or bortez...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Immunol
Autori principali: Seckinger, Anja, Hillengass, Jens, Emde, Martina, Beck, Susanne, Kimmich, Christoph, Dittrich, Tobias, Hundemer, Michael, Jauch, Anna, Hegenbart, Ute, Raab, Marc-Steffen, Ho, Anthony D., Schönland, Stefan, Hose, Dirk
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2018
Soggetti:
Immunology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6062598/
https://ncbi.nlm.nih.gov/pubmed/30079070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01676
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi